Oncology News | pharmaphorum

News

Illumina fined €432m for ignoring Grail merger objection

The European Commission has levied a substantial penalty on DNA sequencing giant Illumina for closing its takeover of cancer detection company Grail without EU regulatory

News

ADC pauses Zynlonta lymphoma trial after deaths

Shares in ADC Therapeutics fell sharply after the company said it had suspended a trial of Zynlonta in previously untreated diffuse large B-cell lymphoma (DLBCL) patients

News

TIGIT underwhelms again as Novartis ducks out

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered

News

Gene sequencing for lung cancer under-used in Europe

There is plenty of evidence that next-generation sequencing (NGS) for lung cancer can improve patient outcomes and save healthcare systems money, but access across Europe

News

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

Johnson & Johnson has bolstered its oncology pipeline by licensing a drug from Nanobiotix designed to enhance the effectiveness of radiotherapy for solid tumours.

News

FDA grants Priority Review of Astellas’ zolbetuximab BLA

Astellas Pharma Inc has announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review of its zolbetuximab Biologics License Application

Illumina fined €432m for ignoring Grail merger objection

ADC pauses Zynlonta lymphoma trial after deaths

TIGIT underwhelms again as Novartis ducks out

Gene sequencing for lung cancer under-used in Europe

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

FDA grants Priority Review of Astellas’ zolbetuximab BLA

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks